New Therapeutic Strategies for EGFR Mutant Lung Cancer - Enduring
Medical staff requested a series of lectures on the landscape of cancer care. Perspectives from thought leaders helps to revitalize the medical staff and develop innovative ideas on ways they can improve and impact patient care as well as research methods and technology, in addition to creating connections which may result in the eventual treatment options which may cure cancer.
The activity content is oriented to address the educational needs of physicians, nurses and all healthcare professionals interested in the subject matter.
- Examine current clinical use of EGFR inhibitors
- Discuss the mechanisms of resistance to EGFR targeted therapies in lung cancer
- Outline the current and upcoming treatment strategies being used to overcome drug resistance to EGFR targeted therapies
- Discuss how to approach and discuss the management of infectious diseases based on patient's beliefs, religion and cultural background
This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.
As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 24 months. Faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships with any ineligible company, which is defined as any entity whose primary business is to produce, market , sell, re-sell or distribute healthcare products used by or on patients. To comply with more intense scrutiny by accreditation agencies, content whose faculty has disclosed any relevant financial relationships with an ineligible company, have been peer reviewed prior to presenting and any potential conflicts relative to the previous disclosure have been resolved.
Presenter: Dr. Pasi A. Jänne has indicated the following relevant financial relationships: Consultant for Abbvie, Accutar Biotech, Allorion Therapeutics, AstraZeneca, Bayer, Biocartis, Boehringer Ingelheim, Chugai Pharmaceuticals Co., LTD., Daiichi Sankyo, DualityBio, Eisai Co., LTD., Eli Lilly, Frontier Medicines, Hongyun Biotechnology, Merus, Mirati Therapeutics, Monte Rosa Therapeutics, Novartis, Nuvalent, Pfizer, Roche/Genentech, Sanofi, Scorpion Therapeutics, SFJ Pharmaceuticals, Silicon Therapeutics, Takeda Oncology, Transcenta, and Voronoi; Grant/Research Support for Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, PUMA, Revolution Medicines, and Takeda Oncology; and other financial/material (Royalties) for LabCorp
The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.
City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.
The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.
This activity has received no commercial support.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hour toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this New Therapeutic Strategies for EGFR Mutant Lung Cancer - Enduring for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Attendance
You must be logged in to access this Enduring.
If you are a New User, please create an account first, by clicking on "Register".
Once Logged in:
Click on "Start Activity" to access the educational content for this Enduring activity.
In order to earn credit for this activity, participants must:
- Read learning objectives and faculty disclosures
- View Enduring Activity Video
- Complete the evaluation
Upon satisfactory completion, you will have the option to receive a print out of your certificate.
If you have questions regarding this process, please contact the City of Hope Continuing Medical Education at 626-218-5622 or email@example.com
Estimated timeframe for completion of this activity, including the time to complete the evaluation is 1.0 hour.